SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 12,795.00 |
| Book Value / Share | 3.13 |
| Price / Book | n/a |
| NCAV ($M) | -27,566.00 |
| NCAV / Share | -6.75 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.15 |
| Return on Assets (ROA) | 0.08 |
| Return on Equity (ROE) | 0.44 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.62 |
| Current Ratio | 0.88 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18,644.00 |
| Assets | 59,005.00 |
| Liabilities | 46,210.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 30,328.00 |
| Operating Income | 7,914.00 |
| Net Income | 4,928.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 6,768.00 |
| Cash from Investing | -1,595.00 |
| Cash from Financing | -5,641.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Dodge & Cox | 5.80 | 6.53 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 479,941 | 2,289,896 | 20.96 | |
| 502,248 | 3,800,880 | 13.21 | |
| 280,156 | 1,623,882 | 17.25 | |
| 398,882 | 2,636,945 | 15.13 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – AbbVie Inc. | ABT – Abbott Laboratories |
| ADCT – ADC Therapeutics SA | ANRO – Alto Neuroscience, Inc. |
| ANVS – Annovis Bio, Inc. |